Analysis of market scale of peptide drugs
Polypeptides are a class of compounds formed by multiple amino acids linked by peptide bonds. They are usually composed of 10-100 amino acid molecules. Their connection mode is the same as that of proteins, and the relative molecular weight is less than 10000.
Polypeptides widely exist in organisms, and tens of thousands of polypeptides have been found in organisms. They widely participate in and regulate the functional activities of various systems, organs, tissues and cells, and play an important role in life activities.
As a subdivision of the drug market, peptide has been widely used in the prevention, diagnosis and treatment of cancer, hepatitis, diabetes, AIDS and other diseases due to its wide indications, high safety and significant curative effect. With the continuous innovation of peptide drug molecular design technology and peptide drug delivery technology, the key problems (not oral, short half-life, poor cell membrane permeability, etc.) that restrict the clinical use of peptide drugs have been continuously broken through.
In recent years, polypeptide drugs have shown outstanding performance in rare diseases and chronic diseases, such as glatelle, liraglutide, somaluptide, dulaglutide, tripatide, linalopide, leuprorelin, pucanatide and other heavy drugs are emerging.
We will conduct statistical analysis on the peptide market size in the global, Chinese and characteristic disease segments to illustrate the excellent performance of peptide drugs in clinical use.
1.1 global peptide drug market size
When we count the peptide drug market, we do not include insulin peptides. If we add insulin, the overall market is about 70 billion US dollars.
1.2 market scale of peptide drugs in China
The statistical data of peptide drug market in China is different from that of global market in terms of sources and product types. Generic drugs are the main products in Chinese market (some data are not included in global market due to Database Collection). Animal and plant extracted peptides with Chinese market characteristics are not available in global market data, which accounts for a relatively high proportion in China’s market data.
1.3 classification market scale of peptide drug products
We summarize the market of several hot product fields of polypeptide drugs at present, and we can see that polypeptide drugs have good performance in the fields of chronic diseases and rare diseases. In particular, diabetes, cancer, intestinal diseases and other areas of performance is particularly prominent.
Peptide new drug research and development is more suitable for cdmo mode
Peptide as a subdivision of the drug market, due to the particularity of its production process, new drug R & D enterprises will choose cdmo / CrO (custom peptide) enterprises for cooperation in the early stage of their research and development. The main reasons are as follows:
1) Cost factor: due to the particularity of peptide drug production process, it is unable to use the R & D and production equipment of small molecule drugs and biological drugs. If the general new drug R & D enterprises arrange peptide drugs between 1-2, it is extremely uneconomical to establish a complete set of hardware facilities for peptide drug R & D and production from the perspective of cost.
2) Efficiency factors and success rate: due to the particularity of peptide drug products and their synthesis technology, there is a big difference in pharmaceutical research (process research, impurity research, method research, structure identification, etc.) between peptide drugs and small molecular chemical drugs and biological drugs. Therefore, cooperation with more professional peptide cdmo companies can make peptide new drugs more quickly on the market and reduce the research of new drugs Risk of failure.
3) Compliance: due to the particularity of polypeptide drugs, regulatory authorities give them special regulatory and approval policies, so it is necessary to use industry experts focusing on this field to reduce the risks in the process of R & D and production. However, the general new drug companies will not reserve talents in the subdivision fields such as peptides, and the R & D and production systems will not carry out corresponding management according to the requirements of peptide drug compliance.
Competition pattern of polypeptide cdmo
Polypeptide drugs are different from small molecule chemical drugs and biological drugs in research and development, production and supervision. Therefore, the development of polypeptide drugs industry is independent of small molecular chemical drugs and biological drugs.
Due to the uniqueness of peptide industry and development process, peptide cdmo enterprises have more diversified ways
3.1 customized peptide service (CRO) transforming peptide cdmo
At present, these enterprises account for more than 50% of the peptide industry, mainly serving scientific research institutions, universities, and enterprise new drug research and development teams. With the accumulation of industry experience and resources, as well as the gradual commercialization of service customers, these enterprises will consider expanding the cdmo field in order to continue to get more stable commercial orders.
3.2 transformation of API to cdmo
During the period when generic drugs enjoyed high profits, a number of domestic enterprises started with polypeptide generic drugs. Some enterprises successfully realized the original accumulation of enterprises through polypeptide generic drugs and API, and further carried out the layout of new products, new preparation technology, innovative drugs and internationalization, so as to realize the leapfrog development of enterprises.
Some enterprises met with the “4 + 7” strategy before the development of enterprises As a result, the previous strategic layout failed to achieve corresponding benefits, while the accumulated industry experience and resources in software and hardware, R & D and production can be realized rapidly through cdmo. Domestic benchmarking enterprises based on this model: Chengdu suno, etc.
3.4 small molecule cdmo expands peptide cdmo
With polypeptide drugs becoming the hot spot segmentation of the whole drug market, more and more powerful cdmo industry leaders expand their business to polypeptide cdmo, and the business is developing rapidly, basically according to the annual growth rate of about 100%.
Peptide industry is very suitable for cdmo mode to promote the development and commercialization of peptide new drugs because of its product and industry characteristics. However, after more than 20 years of development, China’s polypeptide industry has not developed any enterprises directly competing with polypeptide and Bachem in Europe. The development scale of domestic cdmo enterprises is about 300 million, and it is difficult to break through again.
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……
How many companies are there in peptide api manufacturer in china? The peptide api market is very promising, and the world is encouraging the development of peptide business. There is a peptide api list on the website Biofda.com, which contains various specifications of peptide APIs for customers to choose from. Shengnuo Technology is a peptide api manufacturer located in Chengdu, a city in southwest China. Not only peptide APIs, but also carnosine custom suppliers and cosmetic peptide suppliers
are many peptide apis manufacture in China, but they are all small-scale companies. The China peptide company such as Sinotech is a leading company in China and has a very high position.
As a Chinese peptide company, Sinotech has been working silently, hoping to become a top peptide company in the world. There are many countries producing peptides in the world, such as bulk drug substance in India, gmp custom peptide in uk, and peptide production in usa. So what is polypeptide? What kind of peptide synthesis supplier should you choose? Follow our website: www.biofda.com, here will tell you the answer.